EA201491120A1 - Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3 - Google Patents

Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3

Info

Publication number
EA201491120A1
EA201491120A1 EA201491120A EA201491120A EA201491120A1 EA 201491120 A1 EA201491120 A1 EA 201491120A1 EA 201491120 A EA201491120 A EA 201491120A EA 201491120 A EA201491120 A EA 201491120A EA 201491120 A1 EA201491120 A1 EA 201491120A1
Authority
EA
Eurasian Patent Office
Prior art keywords
her3
domain
antibodies
directed
growth factor
Prior art date
Application number
EA201491120A
Other languages
English (en)
Inventor
Винфрид Элис
Сет Эттенберг
Эндрю Пол Гарнер
Николь Хаубст
Хитер Хют
Кристиан Карстен Сильвестер Кунц
Элизабет Энн Райзингер Спрэг
Цин Шэн
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201491120A1 publication Critical patent/EA201491120A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Настоящее изобретение относится к антителам или их фрагментам, которые связываются с нелинейным эпитопом в домене 3 рецептора HER3 и ингибируют как лигандзависимую, так и лиганднезависимую передачу сигнала. Изобретение также относится к антителам или их фрагментам, которые связываются с аминокислотными остатками в доменах 3-4 HER3 и ингибируют как лигандзависимую, так и лиганднезависимую передачу сигнала; и к композициям и способам применения таких антител или их фрагментов.
EA201491120A 2011-12-05 2012-12-04 Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3 EA201491120A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566912P 2011-12-05 2011-12-05
PCT/IB2012/056956 WO2013084151A2 (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3

Publications (1)

Publication Number Publication Date
EA201491120A1 true EA201491120A1 (ru) 2015-07-30

Family

ID=47561692

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491120A EA201491120A1 (ru) 2011-12-05 2012-12-04 Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3

Country Status (16)

Country Link
EP (1) EP2788381A2 (ru)
JP (1) JP2015500830A (ru)
KR (1) KR20140099315A (ru)
CN (1) CN104093742A (ru)
AR (1) AR089085A1 (ru)
AU (1) AU2012349739A1 (ru)
BR (1) BR112014013495A8 (ru)
CA (1) CA2857939A1 (ru)
EA (1) EA201491120A1 (ru)
IL (1) IL232950A0 (ru)
IN (1) IN2014CN04374A (ru)
MX (1) MX2014006731A (ru)
SG (1) SG11201402784WA (ru)
TW (1) TW201331225A (ru)
UY (1) UY34488A (ru)
WO (1) WO2013084151A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
CN106459212B (zh) 2014-02-28 2021-07-13 美勒斯公司 结合erbb-2和erbb-3的抗体
JP6755235B2 (ja) 2014-07-16 2020-09-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 低悪性度漿液性癌におけるｈｅｒ３阻害
CN104530237B (zh) * 2014-12-31 2017-09-05 百泰生物药业有限公司 抗Her1的治疗性抗体
ES2865482T3 (es) 2015-10-23 2021-10-15 Merus Nv Moléculas de unión que inhiben el crecimiento del cáncer
JP6729926B2 (ja) * 2016-05-12 2020-07-29 国立大学法人神戸大学 ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法
JP7203426B2 (ja) * 2016-09-15 2023-01-13 ウニヴェルズィテート シュトゥットガルト Ｈｅｒ３に対する抗原結合タンパク質
KR101923641B1 (ko) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
EA201992063A1 (ru) 2017-03-31 2020-03-26 Мерус Н.В. СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
CN111094351A (zh) 2017-08-09 2020-05-01 美勒斯公司 结合EGFR和cMET的抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
AU2010242914B2 (en) * 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
EP3670539A1 (en) * 2009-11-13 2020-06-24 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing her-3 associated diseases
CN102884085B (zh) * 2010-04-09 2016-08-03 Aveo制药公司 抗erbb3抗体
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
DK2707391T3 (en) * 2011-05-13 2018-02-05 Gamamabs Pharma ANTIBODIES AGAINST HER3
EP2736928B1 (en) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3

Also Published As

Publication number Publication date
KR20140099315A (ko) 2014-08-11
MX2014006731A (es) 2015-06-04
BR112014013495A2 (pt) 2017-06-13
IL232950A0 (en) 2014-07-31
TW201331225A (zh) 2013-08-01
CA2857939A1 (en) 2013-06-13
UY34488A (es) 2013-07-31
CN104093742A (zh) 2014-10-08
IN2014CN04374A (ru) 2015-09-04
AR089085A1 (es) 2014-07-30
AU2012349739A1 (en) 2014-06-26
WO2013084151A2 (en) 2013-06-13
EP2788381A2 (en) 2014-10-15
JP2015500830A (ja) 2015-01-08
WO2013084151A3 (en) 2014-01-03
SG11201402784WA (en) 2014-06-27
BR112014013495A8 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
EA201491120A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3
MX336197B (es) Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
UA106070C2 (ru) Антитело, которое специфически связывается с egfr и her3
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
MX350957B (es) Moleculas de union especificas para her3 y usos de las mismas.
GEP20125612B (en) Prlr-specific antibody and usage thereof
EP3786183A3 (en) Antigen binding constructs to cd3
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
NZ604510A (en) Dilutable biocidal compositions and methods of use
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
NZ608033A (en) Anti-ox40 antibodies and methods of using the same
MX336196B (es) Proteinas de union a amiloide beta.
MX2013013832A (es) Proteínas de unión receptoras fc.
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EA201390467A1 (ru) Композиции антител и способы применения
EA201390537A1 (ru) Антигенсвязывающие белки, связывающиеся с онкостатином м (osm)
EA200900991A1 (ru) Новые антитела против igf-1r